| Recruiting | A Study of Ivonescimab in People With Leiomyosarcoma NCT07516925 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sa NCT07169344 | Oslo University Hospital | Phase 2 |
| Recruiting | Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma NCT06528769 | Gabriel Tinoco | Phase 2 |
| Recruiting | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Pa NCT06975293 | STORM Therapeutics LTD | Phase 1 / Phase 2 |
| Recruiting | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986 | Fudan University | Phase 2 |
| Not Yet Recruiting | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897 | ECOG-ACRIN Cancer Research Group | N/A |
| Not Yet Recruiting | The Role of Pre-Surgical Tru - Cut Biopsy in the Management of Atypical Myometrial Lesions NCT06521060 | Charles University, Czech Republic | — |
| Recruiting | A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tiss NCT06308419 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients NCT06875700 | University of Utah | — |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Recruiting | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154 | HRYZ Biotech Co. | Phase 2 |
| Unknown | Exploring Clinical Trial Experiences of People With Leiomyosarcoma NCT05548179 | Power Life Sciences Inc. | — |
| Recruiting | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Par NCT06088290 | PharmaMar | Phase 3 |
| Recruiting | Localized Leiomyosarcoma Biomarker Protocol NCT04925089 | University of Michigan Rogel Cancer Center | — |
| Active Not Recruiting | Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2 NCT05427461 | Institut Claudius Regaud | N/A |
| Recruiting | Metastatic Leiomyosarcoma Biomarker Protocol NCT05653388 | University of Michigan Rogel Cancer Center | — |
| Terminated | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) NCT05269355 | PTC Therapeutics | Phase 2 / Phase 3 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Terminated | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma NCT05116683 | Benjamin Izar | Phase 2 |
| Completed | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarco NCT05080790 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Unknown | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents NCT05094804 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Recruiting | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma NCT04535271 | Sarcoma Oncology Research Center, LLC | Phase 2 |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Unknown | Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma NCT05204524 | Chinese Academy of Medical Sciences | N/A |
| Recruiting | A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases NCT04554914 | Pierre Fabre Medicament | Phase 2 |
| Terminated | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With NCT04996004 | Pfizer | Phase 2 |
| Completed | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients NCT04811196 | University Health Network, Toronto | Phase 1 |
| Recruiting | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma NCT04031677 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Active Not Recruiting | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma NCT04624178 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma NCT04420975 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sar NCT04055220 | Centre Leon Berard | N/A |
| Completed | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas NCT04242238 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma T NCT02923778 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Study of LY3435151 in Participants With Solid Tumors NCT04099277 | Eli Lilly and Company | Phase 1 |
| Unknown | Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas NCT04214457 | Igenomix | — |
| Completed | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas NCT03899805 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma NCT03437070 | University of Miami | Phase 1 |
| Active Not Recruiting | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors NCT03851614 | University Health Network, Toronto | Phase 2 |
| Completed | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LM NCT03761095 | PTC Therapeutics | Phase 1 |
| Withdrawn | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin NCT03773510 | Italian Sarcoma Group | Phase 3 |
| Completed | M6620 (VX-970) in Selected Solid Tumors NCT03718091 | Massachusetts General Hospital | Phase 2 |
| Unknown | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) NCT03420014 | Philogen S.p.A. | Phase 2 |
| Completed | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma NCT03526679 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Unknown | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas NCT03989596 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Terminated | Vorinostat (SAHA) in Uterine Sarcoma NCT03509207 | Medical University of Graz | Phase 2 |
| Recruiting | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial S NCT03016819 | Advenchen Laboratories, LLC | Phase 3 |
| Completed | A Study of Nivolumab in Selected Uterine Cancer Patients NCT03241745 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Terminated | Patient Reported Outcome Measures (PROMs) With Trabectedin NCT03959033 | University of Leeds | — |
| Terminated | Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors NCT02940041 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Unknown | Detection of Circulating Tumor Cells in Patients With Sarcomas NCT02983539 | AC Camargo Cancer Center | — |
| Recruiting | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients NCT02275286 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients Wi NCT02180867 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Lipos NCT02247544 | Italian Sarcoma Group | Phase 2 |
| Completed | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma NCT01956084 | Catherine Bollard | Phase 1 |
| Completed | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases NCT01447056 | Baylor College of Medicine | Phase 1 |
| Completed | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas NCT01426633 | Heidelberg University | Phase 1 |
| Completed | Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine NCT01442662 | UNICANCER | Phase 2 |
| Terminated | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft T NCT01418001 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma NCT02249702 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes NCT00887809 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma NCT00856050 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Sorafenib and Dacarbazine in Soft Tissue Sarcoma NCT00837148 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma NCT00668148 | Eli Lilly and Company | Phase 2 |
| Completed | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarc NCT00815945 | AGO Study Group | Phase 2 |
| Completed | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lun NCT00503295 | Oncolytics Biotech | Phase 2 |
| Terminated | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma NCT00414076 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma NCT00400569 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Bevacizumab and Radiation Therapy for Sarcomas NCT00356031 | Massachusetts General Hospital | Phase 2 |
| Completed | Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma NCT00282087 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Completed | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants Wi NCT00093080 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma NCT00062868 | Baylor College of Medicine | Phase 1 |
| Completed | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Adv NCT00060944 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |